Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H3GK
|
||||
| Former ID |
DIB005031
|
||||
| Drug Name |
Autologous cell based gene therapy
|
||||
| Synonyms |
Autologous cell based gene therapy (pulmonary hypertension)
|
||||
| Indication | Pulmonary hypertension [ICD9: 416; ICD10:I27.0, I27.2] | Phase 1 | [534588] | ||
| Company |
University of Toronto
|
||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, endothelial | Target Info | Modulator | [526424] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| NetPath Pathway | Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Thromboxane A2 receptor signaling | |||||
| SHP2 signaling | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| PAR1-mediated thrombin signaling events | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.